Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study. Issue 9 (March 2019)

• Record Type: Journal Article
• Authors: Sugiyama, Keiji; Kogure, Yoshihito; Torii, Atsushi; Shiraishi, Kazuhiro; Yamada, Arisa; Ishida, Akane; Shigematsu, Fumie; Nozawa, Kazuki; Niwa, Hideyuki; Oka, Saori; Nakahata, Masashi; Kitagawa, Chiyoe; Oki, Masahide; Saka, Hideo
• Other Names: Sun. YX section editor.
• Is Part Of: Medicine. Volume 98:Issue 9(2019)
• Publication Date: 2019-03
• Subjects: chemotherapy -- nab-paclitaxel -- paclitaxel -- small cell lung cancer; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000014758
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily treated patients should be assessed. Here, we evaluated the efficacy of paclitaxel (PTX) in R/R SCLC patients. A single-institute retrospective chart review was conducted. The primary endpoint was overall survival (OS), whereas the secondary endpoints were progression-free survival (PFS), overall response rate, disease control rate (DCR), and safety. Thirty-one patients (median age, 69 [range, 56–80] years) were analyzed. The median follow-up period was 122 (range, 28–1121) days. The median OS and PFS were 4.4 and 2.2 months, respectively. Adverse events of grade 3 or higher, other than hematological toxicity, were febrile neutropenia and neuropathy. Multivariate analyses identified the following independent predictors of poor OS: performance status and lactate dehydrogenase at the upper limit of normal. PTX monotherapy showed moderate efficacy with acceptable toxicity in heavily treated patients with R/R SCLC patients.